首页 > 最新文献

Actas urologicas espanolas最新文献

英文 中文
The effect of the combination of prostate-specific antigen derivatives with multiparametric prostate magnetic resonance imaging scores on the negative predictive value of it in grey zone patients 前列腺特异性抗原衍生物与多参数前列腺磁共振成像评分相结合对灰色地带患者其阴性预测值的影响。
Pub Date : 2024-04-01 DOI: 10.1016/j.acuroe.2023.10.004
C. Bostancı, D.Ö. Demir

Objective

To calculate the negative predictive value (NPV) of negative multiparametric prostate magnetic resonance imaging (mpMRI), accepted as no lesions on images, when combined with prostate-specific antigen density (PSAD) and free/total prostate-specific antigen ratio (f/t PSA) in grey zone patients.

Methods

191 patients with PSA levels between 4−10 mg/mL and negative mpMRI were analyzed. The NPV of negative mpMRI was calculated according to a PSAD level of <0.15 ng/mL/mL, f/t PSA ratio of >0.15, and a combination of both. Patients were divided into three risk groups according to these two parameters, which were PSAD 0.01−0.07 ng/mL/mL and f/t PSA ratio ≥25 in a low-risk group, PSAD 0.08−0.15 ng/mL/mL, and f/t PSA ratio 0.15−0.24 in an intermediate-risk group and high-risk group, in which PSAD > 0.15 ng/mL/mL and f/t PSA ratio <15.

Results

NPV of negative mpMRI was 92.6% for clinically significant prostate carcinoma (CSPCa). It increased to 97.5% in a low-risk group and decreased to 33.3% for CSPCa in a high-risk group. NPV of negative mpMRI results were so close when combined with PSAD < 0.15 ng/mL/mL and f/t PSA > 15.

Conclusion

f/t PSA ratio might also be used to increase the NPV of mpMRI, like PSAD. We advise not to avoid prostate biopsy when PSAD is >0.15 ng/mL/mL and the f/t PSA ratio is <0.15. However, we need randomized controlled studies with more patients to confirm our study.

目的:计算阴性多参数前列腺磁共振成像(mpMRI)的阴性预测值(NPV),当与灰色地带患者的前列腺特异性抗原密度(PSAD)和游离/总前列腺特异性抗体比率(f/tPSA)相结合时,该成像在图像上被视为无病变。方法:191名PSA水平在4-10之间的患者 mg/ml和阴性mpMRI进行分析。根据0.15的PSAD水平以及两者的组合计算阴性mpMRI的NPV。根据这两个参数将患者分为三个风险组,PSAD为0.01-0.07 低风险组的ng/ml/ml和f/t PSA比值≥25,PSAD 0.08-0.15 在中危组和高危组中,ng/ml/ml和f/t PSA比率为0.15-0.24,其中PSAD > 0.15 结果:临床意义前列腺癌mpMRI阴性的NPV为92.6%。在低风险组中它增加到97.5%,在高风险组中CSPCa降低到33.3%。当与PSAD结合时,阴性mpMRI结果的NPV非常接近  15.结论:f/t-PSA比值也可能与PSAD一样用于增加mpMRI的NPV。当PSAD大于0.15时,我们建议不要避免前列腺活检 ng/ml/ml,f/t PSA比率为
{"title":"The effect of the combination of prostate-specific antigen derivatives with multiparametric prostate magnetic resonance imaging scores on the negative predictive value of it in grey zone patients","authors":"C. Bostancı,&nbsp;D.Ö. Demir","doi":"10.1016/j.acuroe.2023.10.004","DOIUrl":"10.1016/j.acuroe.2023.10.004","url":null,"abstract":"<div><h3>Objective</h3><p>To calculate the negative predictive value (NPV) of negative multiparametric prostate magnetic resonance imaging (mpMRI), accepted as no lesions on images, when combined with prostate-specific antigen density (PSAD) and free/total prostate-specific antigen ratio (f/t PSA) in grey zone patients.</p></div><div><h3>Methods</h3><p>191 patients with PSA levels between 4−10 mg/mL and negative mpMRI were analyzed. The NPV of negative mpMRI was calculated according to a PSAD level of &lt;0.15 ng/mL/mL, f/t PSA ratio of &gt;0.15, and a combination of both. Patients were divided into three risk groups according to these two parameters, which were PSAD 0.01−0.07 ng/mL/mL and f/t PSA ratio ≥25 in a low-risk group, PSAD 0.08−0.15 ng/mL/mL, and f/t PSA ratio 0.15−0.24 in an intermediate-risk group and high-risk group, in which PSAD &gt; 0.15 ng/mL/mL and f/t PSA ratio &lt;15.</p></div><div><h3>Results</h3><p>NPV of negative mpMRI was 92.6% for clinically significant prostate carcinoma (CSPCa). It increased to 97.5% in a low-risk group and decreased to 33.3% for CSPCa in a high-risk group. NPV of negative mpMRI results were so close when combined with PSAD &lt; 0.15 ng/mL/mL and f/t PSA &gt; 15.</p></div><div><h3>Conclusion</h3><p>f/t PSA ratio might also be used to increase the NPV of mpMRI, like PSAD. We advise not to avoid prostate biopsy when PSAD is &gt;0.15 ng/mL/mL and the f/t PSA ratio is &lt;0.15. However, we need randomized controlled studies with more patients to confirm our study.</p></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"48 3","pages":"Pages 238-245"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41224620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of patients with localized prostate cancer and biochemical recurrence in Spain: A medical survey 西班牙对局部前列腺癌和生化复发患者的管理:医疗调查。
Pub Date : 2024-04-01 DOI: 10.1016/j.acuroe.2023.08.002
R. Correa , N. Vidal , A. Quesada-García , R. Marcos , J. Muñoz del Toro , J. Muñoz-Rodríguez

Introduction

The management of patients with prostate cancer (PCa) is established in clinical practice guidelines, which are based on randomized studies according to the level of evidence. In Spain, the degree of compliance with these guidelines in clinical practice is unknown.

Objectives

To describe the profiles of PCa patients at the time of diagnosis and the management of patients with localized PCa and those with BCR in Spain.

Materials & methods

A medical survey was conducted in specialized care (85 urologists [UROs], 64 radiation oncologists [ROs], and 21 medical oncologists [MOs]). Three questionnaires were developed for this study with 22 (UROs and ROs) or 21 questions (MOs).

Results

The annual incidence of PCa was 24,057 in participating hospitals (N = 131). The extrapolated annual incidence in Spain is 40,531 cases. The estimated prevalence of PCa in Spain is 221,689. Of note, 79% and 80% of patients seen by UROs and ROs, respectively had localized PCa at diagnosis. Biopsy was the most used diagnostic test among the three specialties, followed by abdominopelvic computer tomography. More than 90% of patients with BCR underwent standard tests. Next generation imaging tests and PET-choline/PSMA are still used residually. Most patients with localized PCa are currently treated with either surgery or radiotherapy, while for BCR patients, UROs and ROs prefer radiotherapy and MOs androgen deprivation therapy alone or in combination.

Conclusion

This study describes patient profiles at the time of diagnosis and provides an overview of the current therapeutic management of localized PCa and BCR in clinical practice in Spain.

前言:前列腺癌(PCa)患者的治疗方法是由临床实践指南确定的,这些指南是根据随机研究的证据水平制定的。在西班牙,临床实践中对这些指南的遵守程度尚不清楚:描述西班牙 PCa 患者在确诊时的情况,以及对局部 PCa 患者和 BCR 患者的管理:在专科医疗机构(85 名泌尿科医生 [UROs]、64 名放射肿瘤科医生 [ROs] 和 21 名肿瘤内科医生 [MOs])开展了一项医疗调查。本研究编制了三份调查问卷,其中包括 22 个问题(泌尿外科医生和放射肿瘤科医生)或 21 个问题(肿瘤内科医生):结果:参与研究的医院(N = 131)PCa 年发病率为 24 057 例。推断西班牙的年发病率为 40,531 例。估计西班牙 PCa 发病率为 221,689 例。值得注意的是,泌尿外科医生和放射科医生接诊的患者中,分别有 79% 和 80% 在确诊时患有局部 PCa。在三个专科中,活检是最常用的诊断方法,其次是腹盆腔计算机断层扫描。90%以上的 BCR 患者接受了标准检查。新一代成像检查和 PET 胆碱/PSMA 仍在使用中。目前,大多数局部 PCa 患者接受手术或放疗,而对于 BCR 患者,泌尿外科医师和放射科医师更倾向于放疗,放射科医师更倾向于单独或联合使用雄激素剥夺疗法:本研究描述了诊断时的患者概况,并概述了目前西班牙临床实践中对局部 PCa 和 BCR 的治疗方法。
{"title":"Management of patients with localized prostate cancer and biochemical recurrence in Spain: A medical survey","authors":"R. Correa ,&nbsp;N. Vidal ,&nbsp;A. Quesada-García ,&nbsp;R. Marcos ,&nbsp;J. Muñoz del Toro ,&nbsp;J. Muñoz-Rodríguez","doi":"10.1016/j.acuroe.2023.08.002","DOIUrl":"10.1016/j.acuroe.2023.08.002","url":null,"abstract":"<div><h3>Introduction</h3><p>The management of patients with prostate cancer (PCa) is established in clinical practice guidelines, which are based on randomized studies according to the level of evidence. In Spain, the degree of compliance with these guidelines in clinical practice is unknown.</p></div><div><h3>Objectives</h3><p>To describe the profiles of PCa patients at the time of diagnosis and the management of patients with localized PCa and those with BCR in Spain.</p></div><div><h3>Materials &amp; methods</h3><p>A medical survey was conducted in specialized care (85 urologists [UROs], 64 radiation oncologists [ROs], and 21 medical oncologists [MOs]). Three questionnaires were developed for this study with 22 (UROs and ROs) or 21 questions (MOs).</p></div><div><h3>Results</h3><p>The annual incidence of PCa was 24,057 in participating hospitals (<em>N</em> = 131). The extrapolated annual incidence in Spain is 40,531 cases. The estimated prevalence of PCa in Spain is 221,689. Of note, 79% and 80% of patients seen by UROs and ROs, respectively had localized PCa at diagnosis. Biopsy was the most used diagnostic test among the three specialties, followed by abdominopelvic computer tomography. More than 90% of patients with BCR underwent standard tests. Next generation imaging tests and PET-choline/PSMA are still used residually. Most patients with localized PCa are currently treated with either surgery or radiotherapy, while for BCR patients, UROs and ROs prefer radiotherapy and MOs androgen deprivation therapy alone or in combination.</p></div><div><h3>Conclusion</h3><p>This study describes patient profiles at the time of diagnosis and provides an overview of the current therapeutic management of localized PCa and BCR in clinical practice in Spain.</p></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"48 3","pages":"Pages 218-227"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2173578623001002/pdfft?md5=98e0c64d8ebb8a4637c34d8285caad92&pid=1-s2.0-S2173578623001002-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10380038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intravesical fat-fluid level as a warning sign of contained bladder perforation: Correlation between cystoscopy and computed tomography findings 膀胱内脂肪流体水平是膀胱穿孔的警示信号:膀胱镜检查与计算机断层扫描结果之间的相关性。
Pub Date : 2024-04-01 DOI: 10.1016/j.acuroe.2023.08.010
P. Montosa Ródenas , M. Gómez Huertas , M.Á. Pérez Rosillo , A.J. Láinez Ramos-Bossini
{"title":"Intravesical fat-fluid level as a warning sign of contained bladder perforation: Correlation between cystoscopy and computed tomography findings","authors":"P. Montosa Ródenas ,&nbsp;M. Gómez Huertas ,&nbsp;M.Á. Pérez Rosillo ,&nbsp;A.J. Láinez Ramos-Bossini","doi":"10.1016/j.acuroe.2023.08.010","DOIUrl":"10.1016/j.acuroe.2023.08.010","url":null,"abstract":"","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"48 3","pages":"Pages 254-256"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10062534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The relationship between infertility and sleep quality in women: Systematic review and meta-analysis 女性不孕症与睡眠质量之间的关系:系统回顾与荟萃分析。
Pub Date : 2024-04-01 DOI: 10.1016/j.acuroe.2023.12.002
N. Gençtürk , A. Yıldız Karaahmet , S. Shafaati Laleh , Z. Guksu

Objectives

This systematic review and meta-analysis study aimed to examine the relationship between infertility and sleep quality in women.

Methods

The literature search was conducted between October and November 2022 with full-text studies from PubMed (MEDLINE), Cochrane, Google Scholar, and Scientific Information Database (SID). The study is based on the recommendations of the Cochrane guidelines. The data were analyzed using the Review Manager computer software (Version 5.3).

Results

A systematic literature review was conducted, with 11 studies included. The meta-analysis revealed a significant difference between infertility and sleep quality in women, that the sleep quality of infertile patients decreased (SMD: −0.75 95% CI: −0.84 to −0.66, Z = 16.46, P < .00001), and that there was a significant difference between infertility and depression (SMD: −0.18 95% CI: −0.27 to −0.09, Z = 4.00, P < .0001).

Conclusion

The results of this study indicate that sleep quality is low in infertile women.

PROSPERO ID: (CRD42023404389).

研究目的本系统综述和荟萃分析研究旨在探讨女性不孕症与睡眠质量之间的关系:文献检索在 2022 年 10 月至 11 月期间进行,全文检索了 PubMed (MEDLINE)、Cochrane、Google Scholar 和科学信息数据库 (SID) 中的研究。研究以 Cochrane 指南的建议为基础。数据使用 Review Manager 计算机软件(5.3 版)进行分析:进行了系统的文献综述,共纳入 11 项研究。荟萃分析表明,女性不孕症与睡眠质量之间存在显著差异,不孕症患者的睡眠质量下降(SMD:-0.75 95% CI:-0.84 至 -0.66,Z = 16.46,P 结论:不孕症患者的睡眠质量与睡眠质量之间存在显著差异:本研究结果表明,不孕妇女的睡眠质量较低。prospero id:(crdxxxxxxxxxxxxx)。
{"title":"The relationship between infertility and sleep quality in women: Systematic review and meta-analysis","authors":"N. Gençtürk ,&nbsp;A. Yıldız Karaahmet ,&nbsp;S. Shafaati Laleh ,&nbsp;Z. Guksu","doi":"10.1016/j.acuroe.2023.12.002","DOIUrl":"10.1016/j.acuroe.2023.12.002","url":null,"abstract":"<div><h3>Objectives</h3><p>This systematic review and meta-analysis study aimed to examine the relationship between infertility and sleep quality in women.</p></div><div><h3>Methods</h3><p>The literature search was conducted between October and November 2022 with full-text studies from PubMed (MEDLINE), Cochrane, Google Scholar, and Scientific Information Database (SID). The study is based on the recommendations of the Cochrane guidelines. The data were analyzed using the Review Manager computer software (Version 5.3).</p></div><div><h3>Results</h3><p>A systematic literature review was conducted, with 11 studies included. The meta-analysis revealed a significant difference between infertility and sleep quality in women, that the sleep quality of infertile patients decreased (SMD: −0.75 95% CI: −0.84 to −0.66, Z = 16.46, <em>P</em> &lt; .00001), and that there was a significant difference between infertility and depression (SMD: −0.18 95% CI: −0.27 to −0.09, Z = 4.00, <em>P</em> &lt; .0001).</p></div><div><h3>Conclusion</h3><p>The results of this study indicate that sleep quality is low in infertile women.</p><p>PROSPERO ID: (CRD42023404389).</p></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"48 3","pages":"Pages 185-203"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139072516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison between the European Randomized Study for Screening of Prostate Cancer (ERSPC) and Prostate Biopsy Collaborative Group (PBCG) risk calculators: Prediction of clinically significant Prostate Cancer risk in a cohort of patients from Argentina 欧洲癌症筛查随机研究(ERSPC)与前列腺活检协作组(PBCG)风险计算器的比较:阿根廷患者队列中具有临床意义的癌症风险预测。
Pub Date : 2024-04-01 DOI: 10.1016/j.acuroe.2023.10.002
P.M. Orbe Villota , J.A. Leiva Centeno , J. Lugones , P.G. Minuzzi , S.M. Varea

Objective

To compare the performance of the risk calculators of the European Randomized Study for Screening of Prostate Cancer (ERSPC) and the Prostate Biopsy Collaborative Group (PBCG) in predicting the risk of presenting clinically significant prostate cancer.

Material and methods

Retrospectively, patients who underwent prostate biopsy at Sanatorio Allende Cerro, Ciudad de Córdoba, Argentina, were identified from January 2018 to December 2021. The probability of having prostate cancer was calculated with the two calculators separately and then the results were compared to establish which of the two performed better. For this, areas under the curve (AUC) were analyzed.

Results

250 patients were included, 140 (56%) presented prostate cancer, of which 92 (65.71%) had clinically significant prostate cancer (Gleason score ≥7). The patients who presented cancer were older, had a higher prostate-specific antigen (PSA) value, and had a smaller prostate size. The AUC to predict the probability of having clinically significant prostate cancer was 0.79 and 0.73 for PBCG-RC and ERSPC-RC respectively (P = 0.0084).

Conclusion

In this cohort of patients, both prostate cancer risk calculators performed well in predicting clinically significant prostate cancer risk, although the PBCG-RC showed better accuracy.

目的:比较欧洲癌症筛查随机研究(ERSPC)和前列腺活检协作小组(PBCG)的风险计算器在预测临床显著前列腺癌症风险方面的性能。材料和方法:回顾性分析,2018年1月至2021年12月,在阿根廷科尔多瓦城Sanatorio Allende Cerro接受前列腺活检的患者。分别用两个计算器计算患前列腺癌症的概率,然后将结果进行比较,以确定两者中哪一个表现更好。为此,分析了曲线下面积(AUC)。结果:纳入患者250例,其中140例(56%)为前列腺癌,其中92例(65.71%)为有临床意义的癌症(Gleason评分≥7)。癌症患者年龄较大,前列腺特异性抗原(PSA)值较高,前列腺大小较小。PBCG-RC和ERSPC-RC预测具有临床意义的前列腺癌症概率的AUC分别为0.79和0.73(P = .0084)。结论:在这组患者中,两种前列腺癌症风险计算器在预测临床显著的前列腺癌症风险方面都表现良好,尽管PBCG-RC显示出更好的准确性。
{"title":"Comparison between the European Randomized Study for Screening of Prostate Cancer (ERSPC) and Prostate Biopsy Collaborative Group (PBCG) risk calculators: Prediction of clinically significant Prostate Cancer risk in a cohort of patients from Argentina","authors":"P.M. Orbe Villota ,&nbsp;J.A. Leiva Centeno ,&nbsp;J. Lugones ,&nbsp;P.G. Minuzzi ,&nbsp;S.M. Varea","doi":"10.1016/j.acuroe.2023.10.002","DOIUrl":"10.1016/j.acuroe.2023.10.002","url":null,"abstract":"<div><h3>Objective</h3><p><span>To compare the performance of the risk calculators of the European Randomized Study for Screening of Prostate Cancer (ERSPC) and the </span>Prostate Biopsy<span> Collaborative Group (PBCG) in predicting the risk of presenting clinically significant prostate cancer.</span></p></div><div><h3>Material and methods</h3><p>Retrospectively, patients who underwent prostate biopsy at Sanatorio Allende Cerro, Ciudad de Córdoba, Argentina, were identified from January 2018 to December 2021. The probability of having prostate cancer was calculated with the two calculators separately and then the results were compared to establish which of the two performed better. For this, areas under the curve (AUC) were analyzed.</p></div><div><h3>Results</h3><p>250 patients were included, 140 (56%) presented prostate cancer, of which 92 (65.71%) had clinically significant prostate cancer (Gleason score ≥7). The patients who presented cancer were older, had a higher prostate-specific antigen (PSA) value, and had a smaller prostate size. The AUC to predict the probability of having clinically significant prostate cancer was 0.79 and 0.73 for PBCG-RC and ERSPC-RC respectively (<em>P</em> <!-->=<!--> <!-->0.0084).</p></div><div><h3>Conclusion</h3><p>In this cohort of patients, both prostate cancer risk calculators performed well in predicting clinically significant prostate cancer risk, although the PBCG-RC showed better accuracy.</p></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"48 3","pages":"Pages 210-217"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41224615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correlation between LHCGR and NR5A1 genes polymorphism and male infertility risk LHCGR和NR5A1基因多态性与男性不育风险的相关性。
Pub Date : 2024-04-01 DOI: 10.1016/j.acuroe.2023.10.001
M. Behvarz , S.A. Rahmani , E. Siasi Torbati , S. Danaei Mehrabad , M. Bikhof Torbati

Introduction

Infertility is one of the important phenomena in human reproduction. Genetic factors are the most important cause of male infertility. Here, we aimed to investigate the correlation between idiopathic male infertility and SNPs of the LHCGR (rs2293275) and NR5A1 (rs1057517779) genes in the Iranian-Azeri population.

Methods

This case-control study consisted of 100 males with infertility and 100 healthy males from the Iranian Azeri population. Genomic DNA isolation from whole blood samples and Tetra-primer amplification refractory mutation system-polymerase chain reaction (Tetra-ARMS-PCR) method was used for genotyping. The data analysis was performed by chi-square (χ2) and Fisher’s exact tests.

Results

Genotyping analysis for LHCGR (rs2293275) polymorphism indicated that the frequency of C in the case group was significantly higher than in the control group (P < .05). Moreover, genotyping analysis for NR5A1 (rs1057517779) polymorphism indicated that the frequencies of the A allele and heterozygote GA genotype in the case group were significantly higher than those in the control group (P < .05).

Conclusion

Our study demonstrated that the SNPs of LHCGR (rs2293275) and NR5A1 (rs1057517779) genes may play a critical role in male infertility in the Iranian Azeri population. However, further studies on other ethnic origins with larger sample sizes are essential for accessing more accurate results. Moreover, functional experiments might be needed to understand the role of these polymorphisms in the molecular pathways involved in male fertility.

引言:不孕不育是人类生殖过程中的重要现象之一。遗传因素是导致男性不育的最重要原因。在此,我们旨在研究伊朗-阿塞拜疆人群中特发性男性不育与LHCGR(rs2293275)和NR5A1(rs1057517779)基因SNPs之间的相关性。方法:本病例对照研究由100名不育男性和100名来自伊朗-阿塞拜疆人群的健康男性组成。从全血样本中分离基因组DNA,并采用Tetra引物扩增难治性突变系统聚合酶链式反应(Tetra ARMS PCR)方法进行基因分型。数据分析采用卡方(χ2)和Fisher精确检验。结果:LHCGR(rs2293275)多态性基因分型分析表明,病例组C基因频率明显高于对照组(P 结论:我们的研究表明,LHCGR(rs2293275)和NR5A1(rs1057517779)基因的SNPs可能在伊朗-阿塞拜疆人群的男性不育中起着关键作用。然而,对样本量较大的其他种族起源进行进一步研究对于获得更准确的结果至关重要。此外,可能需要进行功能实验来了解这些多态性在男性生育相关分子途径中的作用。
{"title":"Correlation between LHCGR and NR5A1 genes polymorphism and male infertility risk","authors":"M. Behvarz ,&nbsp;S.A. Rahmani ,&nbsp;E. Siasi Torbati ,&nbsp;S. Danaei Mehrabad ,&nbsp;M. Bikhof Torbati","doi":"10.1016/j.acuroe.2023.10.001","DOIUrl":"10.1016/j.acuroe.2023.10.001","url":null,"abstract":"<div><h3>Introduction</h3><p><span>Infertility is one of the important phenomena in human reproduction. Genetic factors<span><span> are the most important cause of male infertility. Here, we aimed to investigate the correlation between idiopathic male infertility and </span>SNPs of the </span></span><span><span>LHCGR</span></span> (rs2293275) and <em>NR5A1</em> (rs1057517779) genes in the Iranian-Azeri population.</p></div><div><h3>Methods</h3><p>This case-control study consisted of 100 males with infertility and 100 healthy males from the Iranian Azeri population. Genomic DNA isolation from whole blood samples and Tetra-primer amplification refractory mutation system-polymerase chain reaction (Tetra-ARMS-PCR) method was used for genotyping. The data analysis was performed by chi-square (χ2) and Fisher’s exact tests.</p></div><div><h3>Results</h3><p>Genotyping analysis for <em>LHCGR</em> (rs2293275) polymorphism indicated that the frequency of C in the case group was significantly higher than in the control group (<em>P</em> &lt; .05). Moreover, genotyping analysis for <em>NR5A1</em><span> (rs1057517779) polymorphism indicated that the frequencies of the A allele and heterozygote GA genotype in the case group were significantly higher than those in the control group (</span><em>P</em> &lt; .05).</p></div><div><h3>Conclusion</h3><p>Our study demonstrated that the SNPs of <em>LHCGR</em> (rs2293275) and <em>NR5A1</em><span> (rs1057517779) genes may play a critical role in male infertility in the Iranian Azeri population. However, further studies on other ethnic origins with larger sample sizes are essential for accessing more accurate results. Moreover, functional experiments might be needed to understand the role of these polymorphisms in the molecular pathways involved in male fertility.</span></p></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"48 3","pages":"Pages 246-253"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41224616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Usefulness of renal nephrometry scoring systems in the prediction of complications associated to percutaneous image-guided treatment for small renal masses 肾测量评分系统在预测经皮图像引导治疗小肾脏肿块相关并发症中的有用性。
Pub Date : 2024-03-01 DOI: 10.1016/j.acuroe.2023.10.006
A. Abu-Suboh Abadia , A. Abu-Suboh Abadia , L. Mosquera Seoane , P. Gómez Martínez , M.A. Trillo Lista , P. Portela Pereira , M.J. Martínez Barcina , J. Palou Redorta , O. Rodríguez Faba

Introduction

Due to their increasing prevalence and complex management, renal tumors are challenging for health professionals. The study aims to evaluate the usefulness of R.E.N.A.L. and PADUA nephrometry scores in the prediction of complications after percutaneous cryoablation.

Material and methods

The study prospectively analyzed 90 patients with 101 stage T1a renal cell carcinoma (RCC) tumors treated with cryoablation.

Results

Ninety patients with 101 small renal tumors who received cryoablative therapy were investigated. The mean age of the patients was 68 years and 74.4% were male. Most tumors were smaller than 4 cm (89.1%) and the mean PADUA and R.E.N.A.L. scores were 8.65 and 7.35, respectively. Complications were observed in 12 cases. PADUA and R.E.N.A.L. scores demonstrated moderate predictive power (AUC = 0.58 and AUC = 0.63, respectively) for post-cryoablation complications.

Conclusions

Percutaneous cryoablation is a safe and effective treatment for small renal tumors. The R.E.N.A.L. and PADUA renal nephrometry scores have moderate predictive power for complications associated with percutaneous cryoablation of renal tumors.

引言:由于肾肿瘤的发病率越来越高,管理也越来越复杂,肾肿瘤对卫生专业人员来说是一项挑战。本研究旨在评估R.E.N.A.L.和PADUA肾测量评分在预测经皮冷冻消融后并发症方面的有用性。材料和方法:本研究前瞻性分析了90例接受冷冻消融治疗的101期T1a肾细胞癌(RCC)患者。结果:对90例101个肾小肿瘤患者进行了冷冻治疗。患者的平均年龄为68岁,74.4%为男性。大多数肿瘤小于4 平均PADUA和R.E.N.A.L.得分分别为8.65和7.35。并发症12例。PADUA和R.E.N.A.L.评分显示中等预测能力(AUC = 0.58和AUC = 0.63)治疗冷冻消融后并发症。结论:经皮肾小肿瘤冷冻消融是一种安全有效的治疗方法。R.E.N.A.L.和PADUA肾脏测量评分对肾肿瘤经皮冷冻消融相关并发症具有中等预测能力。
{"title":"Usefulness of renal nephrometry scoring systems in the prediction of complications associated to percutaneous image-guided treatment for small renal masses","authors":"A. Abu-Suboh Abadia ,&nbsp;A. Abu-Suboh Abadia ,&nbsp;L. Mosquera Seoane ,&nbsp;P. Gómez Martínez ,&nbsp;M.A. Trillo Lista ,&nbsp;P. Portela Pereira ,&nbsp;M.J. Martínez Barcina ,&nbsp;J. Palou Redorta ,&nbsp;O. Rodríguez Faba","doi":"10.1016/j.acuroe.2023.10.006","DOIUrl":"10.1016/j.acuroe.2023.10.006","url":null,"abstract":"<div><h3>Introduction</h3><p>Due to their increasing prevalence and complex management, renal tumors are challenging for health professionals. The study aims to evaluate the usefulness of R.E.N.A.L. and PADUA nephrometry scores in the prediction of complications after percutaneous cryoablation.</p></div><div><h3>Material and methods</h3><p>The study prospectively analyzed 90 patients with 101 stage T1a renal cell carcinoma (RCC) tumors treated with cryoablation.</p></div><div><h3>Results</h3><p>Ninety patients with 101 small renal tumors who received cryoablative therapy were investigated. The mean age of the patients was 68 years and 74.4% were male. Most tumors were smaller than 4 cm (89.1%) and the mean PADUA and R.E.N.A.L. scores were 8.65 and 7.35, respectively. Complications were observed in 12 cases. PADUA and R.E.N.A.L. scores demonstrated moderate predictive power (AUC = 0.58 and AUC = 0.63, respectively) for post-cryoablation complications.</p></div><div><h3>Conclusions</h3><p>Percutaneous cryoablation is a safe and effective treatment for small renal tumors. The R.E.N.A.L. and PADUA renal nephrometry scores have moderate predictive power for complications associated with percutaneous cryoablation of renal tumors.</p></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"48 2","pages":"Pages 155-161"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41224621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial comment on the article entitled “How to measure intra-renal pressure during flexible URS: historical background, technological innovations and future perspectives” 对题为 "如何测量柔性尿路时的肾内压:历史背景、技术创新和未来展望 "的文章发表编辑评论。
Pub Date : 2024-03-01 DOI: 10.1016/j.acuroe.2024.01.006
J. Sáenz Medina
{"title":"Editorial comment on the article entitled “How to measure intra-renal pressure during flexible URS: historical background, technological innovations and future perspectives”","authors":"J. Sáenz Medina","doi":"10.1016/j.acuroe.2024.01.006","DOIUrl":"10.1016/j.acuroe.2024.01.006","url":null,"abstract":"","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"48 2","pages":"Pages 111-112"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139718217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The best method for erection function in urethroplasty; is excision and primary anastomosis or buccal mucosal graft urethroplasty? 尿道成形术中勃起功能的最佳方法是切除吻合术还是颊粘膜移植尿道成形术?
Pub Date : 2024-03-01 DOI: 10.1016/j.acuroe.2023.11.002
R. Uğur, A. Şimşek

Introduction

The aim of this study is to evaluate and compare erection function (EF) after Excision and Primary Anastomosis Urethroplasty (EPAU) and Buccal Mucosal Graft Urethroplasty (BMGU) in bulbar urethral stricture.

Methods

Patients who underwent urethroplasty were identified retrospectively. The criteria for inclusion in the study were determined as being over 18 years old and under 70 years old, being sexually active. Exclusion criteria are; preoperative severe erectile dysfunction, stricture outside the bulbar urethra, psychosocial incompatibility, urethral stricture related to pelvic fracture, follow-up time less than a year. As the primary endpoint, the International Index of Erectile Function-5 (IIEF-5) was determined as a comparison of EF in the preoperative and third, sixth and twelfth months after surgery. The secondary endpoint was the evaluation of the effects of demographic data, stricture and treatment characteristics on EF.

Results

Fifty patients were identified considering the inclusion/exclusion criteria. It was observed that there were 30 patients who underwent EPAU and 20 patients who underwent BMGU. At the third month after surgery, EF showed a statistically significant decrease in the EPAU group. In both patient groups, it was observed that the early negative effects after the operation in EF started to improve in the sixth month and returned to the baseline level by the first year.

Conclusion

EPAU and BMGU techniques have a similar effect on EF in the medium and long term. Both methods can be used safely and effectively in the appropriate patient group.

摘要:本研究的目的是评价和比较球尿道狭窄切除术和一期吻合尿道成形术(EPAU)和颊粘膜移植尿道成形术(BMGU)后的勃起功能(EF)。方法:对行尿道成形术的患者进行回顾性分析。纳入研究的标准确定为18岁以上,70岁以下,性活跃。排除标准是;术前严重勃起功能障碍,球外尿道狭窄,心理社会不适应,尿道狭窄伴骨盆骨折,随访时间少于一年。作为主要终点,国际勃起功能指数-5 (IIEF-5)被确定为术前与术后第3、6和12个月的勃起功能指数的比较。次要终点是评估人口统计数据、结构和治疗特征对EF的影响。结果:根据纳入/排除标准确定了50例患者。观察到EPAU患者30例,BMGU患者20例。术后第3个月,EPAU组EF下降有统计学意义。在两组患者中,观察到EF手术后的早期负面影响在第六个月开始改善,并在第一年恢复到基线水平。结论:EPAU技术和BMGU技术对EF的中长期疗效相似。这两种方法都可以在适当的患者群体中安全有效地使用。
{"title":"The best method for erection function in urethroplasty; is excision and primary anastomosis or buccal mucosal graft urethroplasty?","authors":"R. Uğur,&nbsp;A. Şimşek","doi":"10.1016/j.acuroe.2023.11.002","DOIUrl":"10.1016/j.acuroe.2023.11.002","url":null,"abstract":"<div><h3>Introduction</h3><p>The aim of this study is to evaluate and compare erection function (EF) after Excision and Primary Anastomosis<span><span> Urethroplasty (EPAU) and Buccal Mucosal Graft Urethroplasty (BMGU) in bulbar </span>urethral stricture.</span></p></div><div><h3>Methods</h3><p>Patients who underwent urethroplasty were identified retrospectively. The criteria for inclusion in the study were determined as being over 18 years old and under 70 years old, being sexually active. Exclusion criteria are; preoperative severe erectile dysfunction<span>, stricture outside the bulbar urethra, psychosocial incompatibility, urethral stricture related to pelvic fracture<span>, follow-up time less than a year. As the primary endpoint, the International Index of Erectile Function-5 (IIEF-5) was determined as a comparison of EF in the preoperative and third, sixth and twelfth months after surgery. The secondary endpoint was the evaluation of the effects of demographic data, stricture and treatment characteristics on EF.</span></span></p></div><div><h3>Results</h3><p>Fifty patients were identified considering the inclusion/exclusion criteria. It was observed that there were 30 patients who underwent EPAU and 20 patients who underwent BMGU. At the third month after surgery, EF showed a statistically significant decrease in the EPAU group. In both patient groups, it was observed that the early negative effects after the operation in EF started to improve in the sixth month and returned to the baseline level by the first year.</p></div><div><h3>Conclusion</h3><p>EPAU and BMGU techniques have a similar effect on EF in the medium and long term. Both methods can be used safely and effectively in the appropriate patient group.</p></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"48 2","pages":"Pages 170-176"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138049122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transplant renal artery stenosis: Study of incidence using doppler ultrasound, risk factors and analysis is effect in graft outcomes 移植肾动脉狭窄:利用多普勒超声研究发病率、风险因素并分析其对移植结果的影响。
Pub Date : 2024-03-01 DOI: 10.1016/j.acuroe.2023.08.004
C. Calzas Montalvo , J. Medina-Polo , N.R. Miranda Utrera , S. Juste Álvarez , A. de la Calle Moreno , M.P. Caro González , R. Santos Perez de la Blanca , M. Hernández Arroyo , E. Peña Vallejo , J. Teigell Tobar , J.M. Duarte Ojeda , M. Pamplona Casamayor , Á. Tejido Sánchez , L. García González , A. Arrébola Pajares , Á. Sánchez Guerrero , J. Rodríguez de la Calle , A. Rodríguez Antolín

Introduction and objectives

Transplant renal artery stenosis (TRAS) is a vascular complication after kidney transplantation which estimated incidence is 13%. It could cause refractory arterial hypertension, kidney dysfunction and premature death in transplant recipients.

Methods

We carried out a retrospective study including every patient who underwent renal transplantation between 2014 and 2020. They were evaluated with a systematic post-transplant renal Doppler ultrasound. To identify independent risk factors for transplant renal artery stenosis we performed a multivariate analysis.

Results

Seven hundred twenty-four kidney transplants were included, 12% ​​were living donors and 88% were deceased donors. The mean age was 54.8 in recipients and 53 in donors. Transplant renal artery stenosis was diagnosed in 70 (10%) recipients, the majority in the first 6 months after surgery. 51% of patients with transplant renal artery stenosis were managed conservatively. The multivariate analysis showed diabetes mellitus, graft rejection, arterial resuture and donor body mass index as independent risk factors for transplant renal artery stenosis. Survival of the grafts with transplant renal artery stenosis was 98% at 6 months and 95% at two years.

Conclusions

The systematic performance of Doppler ultrasound in the immediate post-transplant period diagnosed 10% of transplant renal artery stenosis in our cohort. Despite the above risk factors, an adequate monitoring and treatment could avoid the increased risk of graft loss in patients with transplant renal artery stenosis.

导言和目的:移植肾动脉狭窄(TRAS)是肾移植后的一种血管并发症,估计发生率为 13%。它可导致移植受者出现难治性动脉高血压、肾功能障碍和过早死亡:我们进行了一项回顾性研究,包括 2014 年至 2020 年间接受肾移植的所有患者。方法:我们对 2014 年至 2020 年间接受肾移植的所有患者进行了回顾性研究,并对他们进行了移植后肾脏多普勒超声系统评估。为了确定移植肾动脉狭窄的独立风险因素,我们进行了多变量分析:共纳入 724 例肾移植,其中 12% 为活体捐献者,88% 为死亡捐献者。受者的平均年龄为 54.8 岁,供者的平均年龄为 53 岁。70名受者(10%)被诊断出移植肾动脉狭窄,其中大多数是在术后6个月内。51%的移植肾动脉狭窄患者接受了保守治疗。多变量分析显示,糖尿病、移植物排斥反应、动脉缝合和供体体重指数是移植肾动脉狭窄的独立风险因素。移植肾动脉狭窄患者6个月的存活率为98%,两年的存活率为95%:结论:在移植后的第一时间系统地进行多普勒超声检查,可以诊断出我们队列中10%的移植肾动脉狭窄。尽管存在上述风险因素,但适当的监测和治疗可避免移植肾动脉狭窄患者移植物损失风险的增加。
{"title":"Transplant renal artery stenosis: Study of incidence using doppler ultrasound, risk factors and analysis is effect in graft outcomes","authors":"C. Calzas Montalvo ,&nbsp;J. Medina-Polo ,&nbsp;N.R. Miranda Utrera ,&nbsp;S. Juste Álvarez ,&nbsp;A. de la Calle Moreno ,&nbsp;M.P. Caro González ,&nbsp;R. Santos Perez de la Blanca ,&nbsp;M. Hernández Arroyo ,&nbsp;E. Peña Vallejo ,&nbsp;J. Teigell Tobar ,&nbsp;J.M. Duarte Ojeda ,&nbsp;M. Pamplona Casamayor ,&nbsp;Á. Tejido Sánchez ,&nbsp;L. García González ,&nbsp;A. Arrébola Pajares ,&nbsp;Á. Sánchez Guerrero ,&nbsp;J. Rodríguez de la Calle ,&nbsp;A. Rodríguez Antolín","doi":"10.1016/j.acuroe.2023.08.004","DOIUrl":"10.1016/j.acuroe.2023.08.004","url":null,"abstract":"<div><h3>Introduction and objectives</h3><p><span>Transplant renal artery stenosis<span> (TRAS) is a vascular complication after kidney transplantation which estimated incidence is 13%. It could cause refractory arterial hypertension, </span></span>kidney dysfunction and premature death in transplant recipients.</p></div><div><h3>Methods</h3><p><span>We carried out a retrospective study including every patient who underwent renal transplantation between 2014 and 2020. They were evaluated with a systematic post-transplant renal Doppler ultrasound<span>. To identify independent risk factors for transplant renal artery stenosis we performed a </span></span>multivariate analysis.</p></div><div><h3>Results</h3><p>Seven hundred twenty-four kidney transplants were included, 12% ​​were living donors and 88% were deceased donors. The mean age was 54.8 in recipients and 53 in donors. Transplant renal artery stenosis was diagnosed in 70 (10%) recipients, the majority in the first 6 months after surgery. 51% of patients with transplant renal artery stenosis were managed conservatively. The multivariate analysis showed diabetes mellitus, graft rejection<span>, arterial resuture and donor body mass index as independent risk factors for transplant renal artery stenosis. Survival of the grafts with transplant renal artery stenosis was 98% at 6 months and 95% at two years.</span></p></div><div><h3>Conclusions</h3><p><span><span>The systematic performance of Doppler ultrasound in the immediate post-transplant period diagnosed 10% of transplant renal artery stenosis in our cohort. Despite the above risk factors, an adequate monitoring and treatment could avoid the increased risk of </span>graft loss </span>in patients with transplant renal artery stenosis.</p></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"48 2","pages":"Pages 177-183"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10380040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Actas urologicas espanolas
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1